Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings
Airbus Joins Air India A320 Altitude Drop Probe
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
Shein Scales Back Vietnam Operations as US Trade Rules Shift
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 



